09:52 AM EST - ProMIS Neurosciences, Inc. : Has acquired an exclusive, worldwide license to a novel Alzheimer's disease target. A provisional patent application for this target was submitted to the United States Patent Office on Monday, Nov. 9. The amino acid sequence of this novel target has not been disclosed. ProMIS Neurosciences, Inc.
shares T.PMN are trading unchanged at $0.07.
